Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Express Scripts
AstraZeneca
Harvard Business School
Colorcon

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR SF1126


✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for SF1126

Trial ID Title Status Sponsor Phase Summary
NCT00907205 ↗ A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors Completed SignalRX Pharmaceuticals, Inc. Phase 1 The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose.
NCT00907205 ↗ A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors Completed Semafore Pharmaceuticals Phase 1 The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose.
NCT02337309 ↗ SF1126 for Patients With Relapsed or Refractory Neuroblastoma Terminated SignalRX Pharmaceuticals, Inc. Phase 1 SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. Funding Source - FDA OOPD
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for SF1126

Condition Name

Condition Name for
Intervention Trials
Advanced Hepatocellular Carcinoma 1
Advanced or Metastatic Solid Tumors 1
Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Neuroblastoma 1
Neoplasms 1
Carcinoma, Hepatocellular 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SF1126

Trials by Country

Trials by Country for
Location Trials
United States 16
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 3
Georgia 2
North Carolina 1
New York 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SF1126

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 1
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Terminated 2
Active, not recruiting 1
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SF1126

Sponsor Name

Sponsor Name for
Sponsor Trials
SignalRX Pharmaceuticals, Inc. 4
Semafore Pharmaceuticals 1
University of Southern California 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 5
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Colorcon
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.